# US 7,608,625 B2 · Method for treating bruxism and bruxism-related diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,625 B2
- Document ID: US7608625B2
- Status: Granted
- Kind: B2
- Application number: 10/547,796
- Filed: 2004-01-30
- Published: 2006-08-03
- Granted: 2009-10-27
- Earliest claimed: 2003-03-13
- Assignees: Eisai R&D Management Co., Ltd.
- Inventors: Shouichi Miyawaki; Teruko Yamamoto
- Web page: https://patentgrep.com/patent/US7608625B2

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/4164: 1,3-Diazoles
- A61K 31/426: 1,3-Thiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4453: only substituted in position 1, e.g. propipocaine, diperodon
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a preventive or therapeutic agent for bruxism or bruxism-related diseases that contains as an active ingredient at least one selected from the group consisting of proton pump inhibitors, histamine H2 receptor antagonists, and acid pump antagonists. Examples of the proton pump inhibitors include rabeprazole, omeprazole, esomeprazole, lansoprazole, pantoprazole, or tenatoprazole, or salts thereof, or hydrates thereof.

## Claims

### Claim 1

A method for treating bruxism, said method comprising administering rabeprazole or a salt thereof in an amount effective to treat said bruxism to a bruxism patient.

### Claim 2

A method for treating bruxism, said method comprising administering rabeprazole or a salt thereof and famotidine or a salt thereof in an amount effective to treat said bruxism to a bruxism patient.

### Claim 3

A method for treating a bruxism-related disease in a bruxism patient, said method comprising administering rabeprazole or a salt thereof to said bruxism patient in an amount effective to treat said bruxism-related disease, wherein said bruxism-related disease is selected from the group consisting of temporomandibular disorders, tooth hypersensitivity, masseter muscle hypertrophy, masticatory muscle pain, and headache.

### Claim 4

A method for treating a bruxism-related disease in a bruxism patient, said method comprising administering rabeprazole or a salt thereof and famotidine or a salt thereof to said bruxism patient in an amount effective to treat said bruxism-related disease, wherein said bruxism-related disease is selected from the group consisting of temporomandibular disorders, tooth hypersensitivity, masseter muscle hypertrophy, masticatory muscle pain, and headache.

### Claim 5

A method for treating a temporomandibular disorder in a bruxism patient, said method comprising administering rabeprazole or a salt thereof to said patient in an amount effective to treat said temporomandibular disorder.

### Claim 6

A method for treating a temporomandibular disorder in a bruxism patient, said method comprising administering rabeprazole or a salt thereof and famotidine or a salt thereof in an amount effective to treat said temporomandibular disorder.